Clinical Trial Update: EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

View source ↗

Summary

This clinical trial update shows that EXActDNA-003/NSABP B-64 is actively recruiting to study molecular residual disease detection in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Exact Sciences Corporation | Conditions: Breast Cancer | Status: RECRUITING